Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage. - Test2 - elhamkhani - TriplyDB

Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.

Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.

http://www.wikidata.org/entity/Q37685508

about

Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity.

P2860

Q38663434-E85AB4A0-AE9B-4C3A-99D6-E954606A2305

P2860

Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.

http://www.wikidata.org/entity/Q37685508

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Methylphenidate for Treating A ...... Adults With Optimized Dosage.

@en

Methylphenidate for Treating A ...... Adults With Optimized Dosage.

@nl

type

label

Methylphenidate for Treating A ...... Adults With Optimized Dosage.

@en

Methylphenidate for Treating A ...... Adults With Optimized Dosage.

@nl

prefLabel

Methylphenidate for Treating A ...... Adults With Optimized Dosage.

@en

Methylphenidate for Treating A ...... Adults With Optimized Dosage.

@nl

P1433

Q37685508-E130DEEC-4670-4D3C-A301-FCD4806C5196

P1476

Q37685508-164DBAEA-7AB2-40DA-A0FD-18626F02F9EB

P2093

Q37685508-1C0C8802-93CA-45FE-9DC7-4AF21776691F

Q37685508-42032E31-4AC4-4C75-A32A-9829DD1ADDC2

Q37685508-532F496C-1D1F-423A-9950-D6E672FD1F87

Q37685508-85D566B3-7618-4266-A802-127A10A13B03

Q37685508-B4B3402A-F47F-4D1C-8521-278DFC2A0EB2

Q37685508-D48AA7C6-4B78-4FD0-A8C1-3ED6963EB137

Q37685508-FC1C2359-77DA-4E3A-A60E-6D4BF35812E3

P2860

Q37685508-057D8C17-A39C-4E81-AA64-4243F8D03990

Q37685508-0E08A7FD-6B82-4B30-995F-C1D97F574167

Q37685508-18F07237-B225-4A9E-BA33-A658929E77CC

Q37685508-1C432262-F43A-43D3-8897-147ED3291F7D

Q37685508-2285113A-0873-41A3-A449-712925FA3862

Q37685508-27D9B51F-B0F6-4F81-A43E-02BAD916CDC3

Q37685508-2F4E5004-EA4E-45BB-A813-775B70327ACA

Q37685508-332B7C2F-65C7-46D6-835D-729D67AAB75D

Q37685508-3A1CD3C1-302F-48B1-BD23-2154EC89C451

Q37685508-3CB40858-F137-40E6-85BA-D3601A36A806

P2888

Q37685508-CDF04FCE-9FDB-4DED-962D-E2D4330EFBEC

P304

Q37685508-9BF800BE-1C41-4119-8B4E-D273CBA92A9C

P31

Q37685508-B4333134-E00E-422C-A9A6-718F3B59A6A7

P356

Q37685508-138B318E-A038-423A-AB89-B36CC7110668

P433

Q37685508-85560F14-FD39-410C-92BF-195E86985C16

P478

Q37685508-741DAFCA-BBF5-44C8-88B3-B13BE1D2F392

P577

Q37685508-504C3363-AD6E-47EB-BFC3-0C20E3450D2C

P698

Q37685508-28066A23-C9D6-4F65-B84B-D2D16187A35A

P932

Q37685508-903570E0-89AC-4E26-96F2-1FD27B724109

P356

S13318-016-0346-1

P1433

European Journal of Drug Metabolism and Pharmacokinetics

P1476

Methylphenidate for Treating A ...... Adults With Optimized Dosage.

@en

P2093

Irene Rydberg

http://www.w3.org/2001/XMLSchema#string

Maria D Chermá

http://www.w3.org/2001/XMLSchema#string

Martin Josefsson

http://www.w3.org/2001/XMLSchema#string

Olle Hollertz

http://www.w3.org/2001/XMLSchema#string

Per A Gustafsson

http://www.w3.org/2001/XMLSchema#string

Per Woxler

http://www.w3.org/2001/XMLSchema#string

Tomas Trygg

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics and Clinical Effectiveness of Methylphenidate

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis

Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers

Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices

Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.

Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.

Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol.

Metabolism and disposition of methylphenidate-14C: studies in man and animals.

Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.

P2888

s13318-016-0346-1

P304

295-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13318-016-0346-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27220743

http://www.w3.org/2001/XMLSchema#string

P932

5340830

http://www.w3.org/2001/XMLSchema#string